SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-22-022693
Filing Date
2022-02-14
Accepted
2022-02-14 16:05:53
Documents
4
Group Members
D. E. SHAW & CO., L.L.C.D. E. SHAW VALENCE PORTFOLIOS, L.L.C.DAVID E. SHAW

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm225573d18_sc13ga.htm SC 13G/A 65780
2 EXHIBIT 1 tm225573d18_ex1.htm EX-99.1 5886
3 EXHIBIT 2 tm225573d18_ex2.htm EX-99.2 5931
4 EXHIBIT 3 tm225573d18_ex3.htm EX-99.3 5537
  Complete submission text file 0001104659-22-022693.txt   85225
Mailing Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036
Business Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036 2124780000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

IRS No.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Subject) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88625 | Film No.: 22631420
SIC: 8071 Services-Medical Laboratories